Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients

scientific article published on December 2013

Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3748/WJG.V19.I47.8924
P932PMC publication ID3870545
P698PubMed publication ID24379617

P50authorLeonardo MottolaQ59694970
Rosanna SantoroQ59694971
Alessandra MangiaQ60050616
P2093author name stringAlessandra Mangia
Leonardo Mottola
Rosanna Santoro
P2860cites workGenetic variation in IL28B and spontaneous clearance of hepatitis C virusQ24596340
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virusQ24596652
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesQ24632766
Host Genetic Factors and Antiviral Immune Responses to Hepatitis C VirusQ27487445
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceQ28255243
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyQ28269827
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyQ29614896
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CQ29619541
Sofosbuvir for previously untreated chronic hepatitis C infectionQ29620137
EASL Clinical Practice Guidelines: management of hepatitis C virus infectionQ34168383
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.Q34177249
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.Q36967081
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysisQ42913315
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirinQ42980402
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot studyQ42989003
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic responseQ42998430
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patientsQ43001830
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.Q43031828
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patientsQ43033484
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.Q43034706
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infectionQ43034871
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.Q43035545
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virusQ43037069
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological responseQ43041800
Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoringQ44780715
P433issue47
P407language of work or nameEnglishQ1860
P921main subjecthepatitis CQ154869
Hepatitis C virusQ708693
P304page(s)8924-8928
P577publication date2013-12-01
P1433published inWorld Journal of GastroenterologyQ15708885
P1476titleInterleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients
P478volume19

Reverse relations

cites work (P2860)
Q3582422224 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial
Q38266253Cytokines and HCV-related autoimmune disorders
Q40642039Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment.
Q36402309Genetic predictors of the response to the treatment of hepatitis C virus infection
Q37437190HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.
Q36070215Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.
Q35226081Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study
Q34506224Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Q41493589The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection
Q50283919Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3.

Search more.